Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Other Non-Current Assets: 2021-2025

Historic Other Non-Current Assets for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $333,000.

  • Krystal Biotech's Other Non-Current Assets rose 64.04% to $333,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $333,000, marking a year-over-year increase of 64.04%. This contributed to the annual value of $231,000 for FY2024, which is 12.17% down from last year.
  • Per Krystal Biotech's latest filing, its Other Non-Current Assets stood at $333,000 for Q3 2025, which was up 69.04% from $197,000 recorded in Q2 2025.
  • Krystal Biotech's 5-year Other Non-Current Assets high stood at $402,000 for Q1 2023, and its period low was $62,000 during Q3 2021.
  • For the 3-year period, Krystal Biotech's Other Non-Current Assets averaged around $249,000, with its median value being $231,000 (2024).
  • Per our database at Business Quant, Krystal Biotech's Other Non-Current Assets spiked by 337.84% in 2022 and then tumbled by 55.79% in 2024.
  • Over the past 5 years, Krystal Biotech's Other Non-Current Assets (Quarterly) stood at $74,000 in 2021, then soared by 337.84% to $324,000 in 2022, then dropped by 18.83% to $263,000 in 2023, then declined by 12.17% to $231,000 in 2024, then skyrocketed by 64.04% to $333,000 in 2025.
  • Its Other Non-Current Assets stands at $333,000 for Q3 2025, versus $197,000 for Q2 2025 and $218,000 for Q1 2025.